U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.

Slides:



Advertisements
Similar presentations
1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
Advertisements

Chemaxon's chemo-informatics toolkit integration into the Affectis Data Management System Database Automated Data Integration - Example: IC50 Data generated.
The Drug Discovery Process
David M. Pollock Medical College of Georgia Discovery-Academia.
Challenges in new drug discovery in South Asia
2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions Tom Sutula, MD, PhD Department of Neurology, University.
NIAID BioDefense Research: Challenges, Opportunities, & Sustainability
Global New Drug Development – Opportunities for Brazil Jurij Petrin, M.D. ENIFarMed19 Sep 2014.
An Academic Model to Bridge the Valley of Death April 17, 2009 Scott Weir, PharmD, PhD Institute for Advancing Medical Innovation University of Kansas.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Nanotechnology in Drug Discovery- Development and Delivery
National Institutes of Health Office of Extramural Research Matthew Portnoy, Ph.D. SBIR/STTR Program Manager Office of Extramural Research, NIH Commercialization.
National Institute on Aging Richard J. Hodes, M.D. Director,NIA/NIH/DHHS ADC Meeting – NIH Roadmap and Budget October 2003.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.
Translation of Anti-CD22 Monoclonal Antibodies for the Treatment of Lymphoma Joseph M. Tuscano, M.D. Associate Professor of Medicine Department of Internal.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Molecular Library and Imaging Francis Collins, NHGRI Tom Insel, NIMH Rod Pettigrew, NIBIB Building Blocks and Pathways Francis Collins,NHGRI Richard Hodes,
The NIH Roadmap for Medical Research
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Improving Animal and Human Health by Accelerating Veterinary Centered Entrepreneurship.
Commercializing Innovations at Georgetown University
Florida Center of Excellence for Biomolecular Identification and Targeted Therapeutics.
February 2008 William Petros, Pharm.D., FCCP
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.
Advancing Biotechnology Innovation Ming Zhao, PhD NCI SBIR Development Center June 24, 2014.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
Virtual Drug Development in Southern California, A Pre-Clinical Focus in vitro tests to support IND submissions David Johnson, Ph.D. Director, DMPK MicroConstants,
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
Grand Challenges for Nanomedicine and Nanobiology Workshop Houston, Texas August 27 th, 2007.
Public/Private Partnerships in Neuroscience and The George & Ann Ryan Neuroscience Institute.
Marine Drug Development and Delivery Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College of Pharmacy BELGAUM ,
Activities at Academic Research Centers: Identifying Present Activities and Future Opportunities ICORD V February 24, 2009 Jim Cloyd, PharmD Lawrence Weaver.
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Privacy Symposium / HIPAA Summit
Translation and Innovation Mark Chance, PhD Vice Dean for Research School of Medicine October 19, 2015.
ECCR Overview/MLSCN. NIH Roadmap Series of initiatives designed to pursue major opportunities in biomedical research and gaps in current knowledge that.
FDA Office of Orphan Products Development
“28,424 cases of Ebola and still counting—what have we learned
Thomas S. Bundt, PhD., FACHE COL, MS Commander, USAMRIID
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
NIH and the Clinical Research Enterprise Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institute of Health.
MRC Technology an independent life science medical research charity Biotech & Money 2016 Mr Andrew Mercieca, Director of Finance
Benefits of the SBIR/STTR Programs STTR: Small Business Technology Transfer SBIR/STTR Program Goals Stimulate technological innovation.
ICARE Member Reports National Institutes of Health/National Institute of Neurological Disorders and Stroke NIH Mission: NIH is the steward of medical and.
Basic Translational Clinical New Pathways to Discovery Harmonization Target ID & Valid. Phases I-III Research Teams of Future Translational Cores Clinical.
A model collaboration using the Pool Susanne Hollinger, Ph.D., J.D. Chief Intellectual Property Officer Emory University.
독성학 박 대 훈 한약재산업학과
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Big Discoveries, Small.
Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke The Evolving Mission.
FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.
The U.S. National Center for Advancing Translational Sciences CHRISTOPHER P. AUSTIN, M.D. DIRECTOR, NCATS U.S. NATIONAL INSTITUTES OF HEALTH BIO INTERNATIONAL.
Lorenzo Refolo & M-D Kerns
Funding Opportunities for Inborn Errors of Metabolism March 31, 2016
NIHR Invention for Innovation (i4i)
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
SPARC – Washington University LEAP Inventor Challenge Program RFP
Research Overview Jacqueline French, MD Chief Scientific Officer
NIA-AABC May 9th, 2018 Webinar Lorenzo Refolo & Yuan Luo
An Introduction to the NIHR programmes
Drug Design and Drug Discovery
Volume 21, Issue 9, Pages (September 2014)
Neuroscience Biomarker Program
Pillars of WARF Therapeutics: Invest - Develop - Partner
Presentation transcript:

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke American Society for Experimental Therapeutics Annual Meeting March 04-06, 2010 Therapeutic Development Resources at NINDS Bill Matthew Director, Office of Translational Research; NINDS 1 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Pipeline Principles: 101 Basic Research Therapeutics Raw Material & Pump Block Valve Station Final Delivery 2 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Translational Research: The process of using novel, basic research discoveries to develop clinical applications. T1 T2 T1 bench bedside community 3 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Office of Clinical Research Office of Translational Research NINDS Extramural Research 4 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Basic Research - Target ID Assay Hit to Lead Screen for Hit Proof of Principle Lead Optimization PreClincal Candidate – Safety/Tox First in Human Anti-Convulsant Screening Program Exploratory/Developmental Projects in Translational Research Cooperative Program in Translational Research Translational SBIR Blueprint Neurotherapeutics Grand Challenge CounterACT RAID: Rapid Access to Interventional Development Small Molecule Optimization Small Business Program: SBIR & STTR Spinal Muscular Atrophy Project Molecular Libraries (Roadmap) Assay Development (Roadmap) Drug Discovery for Nervous System Disorders NINDS/OTR Activities in Therapeutic Development: NINDS Multiple ICs 5 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Anticonvulsant Screening Program (ASP) Goal: To facilitate the development of drugs for patients with epilepsy, resistant epilepsy and related CNS conditions Screening performed via a contract mechanism using a battery of seizure models Compounds are submitted by a broad base of Investigators: > 500 total Industrial companies (~200) Academic institutions (~300) ASP Database > 29,000 small molecules – SAR chemistry & biology Compounds in clinical development: currently six Contributed to the development of ten marketed anti-convulsant drugs Jim Stables 6 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Exploratory/Developmental Projects in Translational Research Goal: Develop in vivo animal proof-of-concept for efficacy Program (R21) primarily targets four tasks: Creation and validation of screening assays Development of animal models of disease Identification of candidate therapeutics Development of preliminary animal efficacy data However, can be used for any preclinical development task Tom Miller 7 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Cooperative Program in Translational Research Tom Miller Goal: Bring novel compounds and devices to the clinic Cooperative Agreement, Milestone-driven program Significant staff involvement Reviewed by therapy development experts IND/IDE by the end of the research project period 6 filed INDs and 3 Clinical Trials 8 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Cooperative Program in Translational Research U44 Small Business Awards Goal: Facilitate Small Business development of neurotherapeutics Fast-Track (Phase I & II) and Phase II Applications accepted Phase I - identical scope as translational R21 Phase II - identical scope as translational U01 Randy Stewart Tom Miller For Translational 9 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke THE SMA PROJECT Goal: Develop a safe and effective drug for Spinal Muscular Atrophy Develop drugs that increase expression of SMN protein deficient in SMA patients A ‘Virtual Pharma’ network of contracts for industry-style drug development: medicinal chemistry in vitro testing pharmacological and toxicological studies animal model testing Industry-seasoned consultants and advisors to oversee programs Jill Heemskerk Coming Very Soon 10 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Blueprint Neurotherapeutics Grand Challenge Goal: Provide Medicinal Chemistry and Pharm/tox expertise for developing new drugs for nervous system disorders Investigator-initiated drug starting points “Virtual Pharma” model of drug development Provide access to industry-standard services: medicinal chemistry, pharm/tox, phase I clinical trials Provide industry expertise and guidance on committees Develop licensing opportunities Advance compounds through phase I trials Investigator retains IP Entry Requirements: - Hit compound(s) - Primary screening assay - Secondary assays for biological validation Jill Heemskerk Coming Very Soon 11 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Goal: To develop safe and effective therapies and diagnostic technologies for victims of emergency incidents involving exposure to highly toxic chemicals CounterACT Countermeasures Against Chemical Threats David Jett Research Centers of Excellence Individual research projects at academic, government and industry laboratories Cooperative Agreements, Milestone-driven Efficacy screening and preclinical services contracts Interagency Agreements with DoD laboratories 12 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Mark Scheideler Assay Development: Molecular Libraries and Imaging Roadmap Program Goal: Develop assays to identify small molecule interactions via high-throughput screening of compound libraries, and to chemically optimize active compounds as molecular probes 13 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke NIH-RAID NIH Rapid Access to Interventional Development Pre-IND studies All diseases Access to government expertise and contract resources –Production, bulk supply, GMP manufacturing –Pharmacokinetic/ADME studies –IND-directed toxicology, and more 6 successful IND submissions and 4 clinical trials to date Tom Miller Goal: To execute IND-enabling studies for extramural projects 14 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Basic Research - Target ID Assay Hit to Lead Screen for Hit Proof of Principle Lead Optimization PreClincal Candidate – Safety/Tox First in Human Anti-Convulsant Screening Program Exploratory/Developmental Projects in Translational Research Cooperative Program in Translational Research Translational SBIR Blueprint Neurotherapeutics Grand Challenge CounterACT RAID: Rapid Access to Interventional Development Small Molecule Optimization Small Business Program: SBIR & STTR Spinal Muscular Atrophy Project Molecular Libraries (Roadmap) Assay Development (Roadmap) Drug Discovery for Nervous System Disorders NINDS/OTR Activities in Therapeutic Development: NINDS Multiple ICs 15 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Please Contact us… Thank you 16 -Matthew

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Activity Code R01 Research Project R21 Exploratory/Developmental Grants R41 Small Business Technology Transfer (STTR) Grants - Phase I R42 Small Business Technology Transfer (STTR) Grants - Phase II R43 Small Business Innovation Research Grants (SBIR) - Phase I R44 Small Business Innovation Research Grants (SBIR) - Phase II U01 Research Project--Cooperative Agreements U44 Small Business Innovation Research (SBIR) Cooperative Agreements U54 Specialized Center--Cooperative Agreements X01 Resource Access Award grants.nih.gov/grants/funding/funding_program.htm